Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotechnology | Evaluate
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Pierre Fabre engagements | NERLYNX
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
Partners of the Pierre Fabre Group: from health to beauty
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
THE FACES OF BREAST CANCER
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
